Bradley Bibb, Md Pllc | |
49 Highway 62 412, Ash Flat, AR 72513-9594 | |
(870) 994-7301 | |
(870) 994-7488 |
Full Name | Bradley Bibb, Md Pllc |
---|---|
Type | Facility |
Speciality | Podiatrist |
Location | 49 Highway 62 412, Ash Flat, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1770067589 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213E00000X | Podiatrist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Bradley Bibb, Md Pllc 101 W Main St, Hardy, AR 72542-9566 Ph: (573) 718-2570 | Bradley Bibb, Md Pllc 49 Highway 62 412, Ash Flat, AR 72513-9594 Ph: (870) 994-7301 |
News Archive
Fetal Alcohol Spectrum Disorders affects approximately 1 in 20 children in the United States. These catastrophic and irreversible disorders are entirely preventable if no alcohol is used during pregnancy.
In the first national awareness survey on environmental asthma triggers, U.S. Environmental Protection Agency (EPA) has found that fewer than 30 percent of people with asthma are taking simple steps to reduce exposure to asthma triggers. Exposure to asthma triggers such as secondhand smoke, cockroaches, dust mites, mold, and ozone can cause asthma in young children or set off asthma attacks.
A new study over the usefulness of mammography confirms what most people in the breast cancer community already know. Mammograms are one tool in the breast cancer cache: better early detection, widespread awareness and more effective treatments all play a role in reducing deaths from the disease, according to Susan G. Komen for the Cure.
A new study focuses on determining the existence of an age-related heterogeneity in the severity of COVID-19.
Micell Technologies,â„¢ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStentâ„¢ Drug-Eluting Coronary Stent System (MiStent DES).
› Verified 7 days ago